Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Hambrecht Cuts Noven Pharmaceuticals to 'Sell'


WR Hambrecht downgraded Noven Pharmaceuticals (NOVN) to sell.

The FDA said says Noven's Methypatch for Hyperactivity is not approvable. Analyst Louis Webb says he downgraded to sell from buy, and set an $11 12-month target. He says the FDA has given MethyPatch a Non-Approval rating because of "clinical and other issues." He notes at present, the nature of the new drug application deficiency is unclear.

Webb thinks it may take a year or more to rectify the setback. He says in the meantime, Noven's female hormone replacement business, which has been weak, will be the sole earnings driver.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus